Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01356914 | Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden | PHASE2 | COMPLETED | 20 | — | — | May 1, 2011 | Jun 1, 2012 | Oct 12, 2015 | 1 | United Kingdom |
| NCT01211821 | Effect of BMS-914392 on Pharmacokinetics of Metoprolol | PHASE1 | COMPLETED | 18 | — | — | Sep 1, 2010 | Nov 1, 2010 | Feb 2, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment A: BMS-914392 | EXPERIMENTAL | - |
| Treatment B: BMS-914392 | EXPERIMENTAL | - |
| Treatment C: BMS-914392 | EXPERIMENTAL | - |
| Treatment D: Placebo | PLACEBO_COMPARATOR | - |
| metoprolol | OTHER | Treatment A |
| BMS-914392 + metoprolol | EXPERIMENTAL | Treatment B |
| Name | Type | Description |
|---|---|---|
| BMS-914392 | DRUG | Tablets, Oral, 10 mg, Every Day (QD), 20 days |
| Placebo | DRUG | Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days |
| metoprolol | DRUG | Tablets, Oral, 200 mg, once, 1 day |
Inclusion Criteria: * Paroxysmal atrial fibrillation (AF) * Programmable dual chamber pacemaker with appropriate arrhythmia diagnostics. * 1-50% AF burden on pacemaker interrogation at screening. * Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception t...